Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- Accord Healthcare Expands Women's Health with Clomiphene Tablets
- Exploring New Horizons with Oncotelic's Deciparticle™ Platform
- Innovative AI Scheduling Agent Revamps Practice Management
- Refined Energy Welcomes Ken Wheatley to Board, Updates Property Deal
- Revolutionizing Trading: TruTrade's Latest AI Innovations
- XBP Global Strengthens Public Sector Engagement in Europe
- Applied Digital Drives $25M Investment in Innovative Cooling Tech
- Genvor Partners with Tuskegee University to Innovate Peptide Research
- Global Uranium Advances Exploration with Successful Program in Wyoming
- Understanding the Upcoming Fund Mergers and Their Impact
- Silexion Therapeutics Making Progress in Pancreatic Cancer Trials
- EUR/USD and FTSE 100: Investment Insights for Traders
- Amneal Pharmaceuticals Set to Engage Investors at Key Events
- BBSI Celebrates 5 Years of Great Workplace Achievement
- Revolutionizing Remittances: Discover Zigi App from Intermex
- DoctorBox Integrates ColoAlert to Enhance Preventive Health
- Liberty Defense Pursues $5.2 Million Financing for Growth
- G-III Apparel Group Prepares for Upcoming Earnings Conference
- Kura Oncology Celebrates Major KOMZIFTI Sale Milestone
- Next Hydrogen Solutions Inc. Updates Auditor for Growth Ahead
- Rathbones Group Plc Discloses Strategic Stake in Education Firm
- Comanche Biopharma Strengthens Leadership for Global Advancement
- Polyrizon Achieves Milestone in Nasal Spray Manufacturing Upscaling
- QGold Resources Partners with SLR to Enhance Quartz Mountain Project
- Quest Analytics Enhances Partnership with CMS in New Contract
- VCI Global Sets New Standard with $200M Stablecoin Initiative
- Aurora Cannabis Partners with Leafio for Enhanced Access
- Clearmind Medicine Takes Major Leap with CMND-100 Clinical Trial
- Enhancing Transit in Atlanta: Innovative Paratransit Solutions
- Understanding Public Opening Position Disclosures for Unite Group
- Morien Resources Plans Non-Brokered Private Placement Offering
- Yardi Unveils Innovative MH Manager for Housing Operators
- Nuveen Real Estate Secures $650 Million for Debt Fund Growth
- CERo Therapeutics Commences Trading on OTCQB Market Today
- Blackbaud Enhances Stock Repurchase Program to $1 Billion
- FUN88 Enhances Gaming Experience with USDT Payment Option
- Golden Gate Sotheby's Expands with New Fremont Office Launch
- Introducing OrthoPulse Lite: A Breakthrough in Orthodontics
- Innovative Reebok Smartwatch Launch Features VitalOS™ Platform
- BriaCell Set to Unveil Key Breast Cancer Clinical Findings
- Postal Realty Trust Prepares for Major Upcoming Conferences
- Eurozone Inflation Trends and ECB's Policy Outlook
- Key Insights from NRx Pharmaceuticals' Upcoming Call
- Iridium Secures New $85.8 Million Contract for Satellite Services
- CERo Therapeutics Begins Trading on OTCQB Market: A New Chapter
- Ventyx Highlights Strategic Additions and Expanded Studies
- American Rebel Holdings Partners for Rapid Beer Expansion
- Idaho Scientific Chooses QuickLogic's eFPGA for Security Solutions
- Rio Silver Expands Portfolio with Santa Rita Silver Project
- A-GAME Beverages Welcomes Industry Leader Mitchell Krupp
